
Shares of drug developer Polyrizon PLRZ.O rise 12.6% to $14.00 premarket
Co says it will develop an intranasal version of Clearmind’s CMND.O experimental MEAI therapy, being studied for addiction-related brain disorders
CNMD's shares were up 20% at $1.7 premarket
CNMD's MEAI is designed to reshape neural pathways without hallucinations; intranasal delivery may help faster absorption and bypass the liver, per co
Co says its gel-like nasal platform aims to keep drugs longer in the nose and improve targeted delivery
PLRZ shares down over 99%, CNMD down ~41% in 2025